NEW YORK (GenomeWeb News) - The Center for Molecular Medicine will provide genotyping and analysis services to the Children’s Oncology Group to support a study of genetic abnormalities and their association with response to therapies for treatment of childhood leukemia, CMM said today.
CMM, based in Grand Rapids, Mich., said that in the first phase of the study it will analyze up to 2,200 matched samples of DNA from pediatric leukemia patients’ blood samples and their leukemic blasts. The aim is to identify and catalog genetic variations that COG can use in its efforts to develop improved diagnostics and therapeutics for childhood leukemia.
CMM will “identify and catalog about a million key SNPs” in these samples, said CMM executive director Daniel Farkas.
CMM said it will begin testing samples this month, and that Phase I may be completed by spring.
COG and CMM are also “working together to identify sources of funding to expand the study to six to eight thousand more specimens,” CMM said in a statement.
Financial terms of the agreement were not released.
CMM is a clinical diagnostics laboratory formed last year as a joint venture between Spectrum Health and Van Andel Institute.